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Abstract Osteonecrosis of the jaw (ONJ) is a clinical
condition associated with long-term exposure to inhibitors
of bone resorption, mainly bisphosphonates. Denosumab
(DMab) is a human monoclonal antibody of the receptor
activator of nuclear factor kappa-B ligand. It prevents
osteoclast-mediated bone resorption and is widely pre-
scribed for the management of postmenopausal osteopo-
rosis. Whereas ONJ has already been reported in women
treated with DMab, we report for the first time the
development of ONJ, following tooth extraction, in a
male patient treated for idiopathic osteoporosis with DMab.
Due to the constant increase in DMab prescription, for the
management of osteoporosis, in both genders, physicians
should be made aware of this potential risk.
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Osteoporosis is widely considered to be much more prevalent
in women even though approximately 39 % of new
osteoporotic fractures estimated to have occurred worldwide
in the year 2000 were in men [1]. Men have greater morbidity
and mortality rates due to hip fractures compared to women
[2]. Most of the drugs currently available to treat osteoporosis
in women show a similar response in men than that observed in
postmenopausal osteoporosis [1].
A 58-year-old Caucasian man was diagnosed with idio-
pathic, predominantly trabecular, osteoporosis (OP) in June
2012, based on the following:
1. A previous history of three atraumatic rib fractures (2005)
2. A bone mineral density T-score of −2.9 and −1.5 at the
lumbar spine and femoral neck, respectively
3. The prevalence of a morphometric vertebral deformity
(semi quantitative Grade 2) at T8
Serum 25 (OH) Vitamin D was in the lower range of
recommended values [3] (60 nmol/l) and serum intact para-
thormone was slightly abnormal at 27 pg/ml (normal range,
4–26 pg/ml) [1–84 PTH (DiaSorin, Stillwater, MN, USA]
[4]. The absolute 10-year fracture risk calculated with the
FRAX® algorithm was 17 and 3.9 % for major osteoporotic
and hip fracture, respectively. These values are above the
thresholds for therapeutic interventions that were previously
published for Belgium [5, 6].
All investigations for causes of secondary osteoporosis
remained negative. Due to past history of myocardial infarc-
tions (2002 and 2009), hypertension (i.e., controlled with
simvastatin), and the suspicion of a potentially poor adher-
ence to oral medications, denosumab (DMab)(Prolia®,
Amgen) was initiated (July 12) at a dose of 60 mg, given
subcutaneously every 6 months together with daily supple-
mentation of calcium (1 g/day) and vitamin D (800 IU/day).
DMab is a human monoclonal antibody of the receptor
activator of nuclear factor kappa-B ligand (RANKL). It
competes with RANKL for RANK-binding sites, thereby
preventing osteoclast-mediated bone resorption [7]. DMab
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is a well-established, widely-prescribed treatment for the
management of postmenopausal osteoporosis [8].
It should be noted that despite promising clinical results
were published in male patients with low bone mineral
density [9] and notwithstanding DMab was recently shown
to be cost-effective compared to oral bisphosphonates (BP)
in osteoporotic men [10], this chemical entity is not yet
approved nor marketed in Europe for the treatment of oste-
oporosis in males [1].
During DMab treatment (November 2012), extraction of a
right wisdom tooth took (48) place and was followed by a
mild, slightly progressive pain in the right mandible. A
dentist initiated (December 2012) systemic antibiotherapy
(AB) (amoxicillin, 1.5 g/day) and antibacterial mouth rinse
with no impact on the symptoms.
The patient was referred to us (April 2013). Clinical exam-
ination revealed oral lesions with bone exposure. CT of the
right mandible showed an extensive osteolysis, with a seques-
trum in the medullary cavity, surrounded by a periosteal
thickening, highly suggestive of an osteonecrosis of the jaw
(ONJ), subsequent to a mandibular osteomyelitis (Fig. 1).
Concomitant malignant tumor was excluded. Treatment
included AB coverage, removal of necrotic bone, and treat-
ment with a bone anabolic agent (teriparatide, 20 g/day
subcutaneously) with the maintenance of a calcium and
vitamin D daily supplementation.
ONJ is a clinical condition that presents as exposed bone
in the mandible, maxilla, or both, that persists for at least
8 weeks, in the absence of previous radiation and of metas-
tases in the jaw. Whereas no epidemiologic data on the
incidence of ONJ in the general population are available, a
positive relationship was described between ONJ occurrence
and the use of inhibitors of bone resorption (mainly BP) in
patients with multiple myeloma, metastatic breast cancer,
Paget’s disease, osteoporosis, or other skeletal disorders
[11]. Several pathogenic mechanisms have been proposed.
One of them suggests that ONJ can be caused by BP-induced
low-bone turnover, which leads to decreased blood flow and
bone cell necrosis and apoptosis. In conjunction with chronic
oral or dental infection, this leads to the development of
exposed, nonhealing bone areas in the mouth [12]. The use
of inhibitors of bone resorption prevents bone remodeling to
ensure the replacement of defective bone with an equivalent
volume of healthy bone [13].
DMab was previously related to the development of ONJ,
during treatment for sacral giant cell tumor [14], metastatic
bone disease [15], and prostatic adenocarcinoma [16, 17],
the doses of DMab used in metastatic bone diseases being 12
times greater than in the management of OP.
A recent meta-analysis assessing a total of 8,963 patients
of both genders, with a variety of solid tumors, from seven
studies (i.e., the majority of these patients had either prostate
or breast cancer) revealed an overall incidence of ONJ in
cancer patients receiving DMab of 1.7 % (95 % Cl, 0.9–
3.1 %). This study concluded that, in such patients, the use of
DMab is associated with an increased risk of developing
ONJ when compared with BP treatment or placebo, although
the increased risk was not statistically significant between
DMab and BP treatments [18].
In postmenopausal osteoporosis, two cases of ONJ were
described in a cohort of 2,207 women treated with 60 mg
subcutaneously. DMab every 6 months, for 2 years, after
having received a placebo during the previous 3 years [19].
In conclusion, we describe for the first time the develop-
ment of ONJ following tooth extraction, in a male patient,
treated for idiopathic osteoporosis with DMab. Due to the
constant increase in DMab prescription, for the management
of osteoporosis, in both genders, physicians should be made
aware of this potential risk.
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